Jpmorgan Chase & CO Alkermes Plc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Alkermes Plc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 406,087 shares of ALKS stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

406,087

Previous 567,692 28.47%

Holding current value

$10.8 Million

Previous $15.4 Million 36.32%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$23.21 - $27.24 $3.75 Million - $4.4 Million	-161,605 Reduced 28.47%	406,087 $9.79 Million
Q1 2024 May 10, 2024	SELL	$26.4 - $32.56 $701,131 - $864,728	-26,558 Reduced 4.47%	567,692 $15.4 Million
Q4 2023 Feb 12, 2024	BUY	$23.37 - $28.68 $5.45 Million - $6.68 Million	232,993 Added 64.5%	594,250 $16.5 Million
Q3 2023 Nov 14, 2023	BUY	$27.17 - $31.97 $362,447 - $426,479	13,340 Added 3.83%	361,257 $10.1 Million
Q2 2023 Aug 11, 2023	BUY	$28.34 - $33.63 $751,180 - $891,396	26,506 Added 8.25%	347,917 $10.9 Million
Q1 2023 May 18, 2023	BUY	$25.31 - $29.02 $5.49 Million - $6.29 Million	216,740 Added 207.07%	321,411 $9.06 Million
Q1 2023 May 11, 2023	SELL	$25.31 - $29.02 $4.3 Million - $4.93 Million	-169,797 Reduced 61.86%	104,671 $2.95 Million
Q4 2022 Feb 13, 2023	SELL	$21.94 - $26.24 $106,738 - $127,657	-4,865 Reduced 1.74%	274,468 $7.17 Million
Q3 2022 Nov 14, 2022	BUY	$22.0 - $31.87 $91,278 - $132,228	4,149 Added 1.51%	279,333 $6.24 Million
Q2 2022 Aug 11, 2022	BUY	$26.4 - $30.54 $2.88 Million - $3.33 Million	109,135 Added 65.72%	275,184 $8.2 Million
Q1 2022 May 11, 2022	BUY	$23.07 - $27.99 $3.83 Million - $4.65 Million	166,049 New	166,049 $4.37 Million

Others Institutions Holding ALKS

# of Institutions

349

Shares Held

183M

Call Options Held

209K

Put Options Held

89.4K

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.37B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Alkermes Plc. Transaction History